Real World COPD: Association of Morning Symptoms with Clinical and Patient Reported Outcomes

References

• Mapel DW, Roberts MH. New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics 2012;Oct 1; 30(10):869–85.
   PubMed Web of Science ®Google Scholar
• Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011; 11:612.
   PubMed Web of Science ®Google Scholar
• Buist AS, McBurnie MA, Vollmer WM, Gillespier S, Burney P, Mannino DM, BOLD Collaborative Research Group. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007; 370:741–750.
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta analysis. Eur Respir J 2006; 28(3):523–532.
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37:264–272.
   PubMed Web of Science ®Google Scholar
• GOLD PM. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease, 2001. http://www.goldcopd.org/Guidelines/guidelines-resources.html.
   Google Scholar
• Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187 (4):347–365.
   PubMed Web of Science ®Google Scholar
• Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25(8):2043–2048.
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes—a means to understand. Curr Med Res Opin 2008; 24(11):3063–3072.
   PubMed Web of Science ®Google Scholar
• European Society for Opinion and Marketing Research (ESOMAR), International Code of Marketing and Social Research Practice 2007, http: //www.icc.se/reklam/english/engresearch.pdf, accessed 22 August 2013.
   Google Scholar
• U.S. Department of Health & Human Services, Summary of the HIPAA Privacy Rule Aug 2009, www.hhs.gov/ocr/privacy/index.html, accessed 22 August 2013.
   Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psycholpharmacol Bull 1993; 29:321–326.
   Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009 Sep; 34(3):648–654.
   PubMed Web of Science ®Google Scholar
• StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.
   Google Scholar
• Damia ADD, Gimeno JC, Ferrer MJs, Fabregas ML, Folch PA, Paya JM. A study of the effect of proinflammatory cytokines on the epithelial cells of smokers, with or without COPD. Arch Bronconeumol 2011; 47(9):447–453.
   PubMed Web of Science ®Google Scholar
• Julian LJ, Gregorich SE, Earnest G, Eisner MD, Chen H, Blanc PD, Screening for depression in chronic obstructive pulmonary disease. COPD 2009; 6(6):452–458.
   PubMedGoogle Scholar
• Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3(4):1–11.
   PubMedGoogle Scholar
• Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Gil EG, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9:1–12.
   PubMedGoogle Scholar
• D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respiratory Res 2011; 12:156–159.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VKT, Lu Y, Banerji D. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40:1–10.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Singh D, Di Scala L, Drollman A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J COPD 2012; (7):503–513.
   Google Scholar
• Liu XL, Tan JY, Wang T, Zhang Q, Zhang M, Mao LQ, Chen JX. Effectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials. Rehabil Nurs Epub 2013/06/18.
   Google Scholar
• Ramponi S, Tzani P, Aiello M, Marangio E, Clini E, Chetta A. Pulmonary rehabilitation improves cardiovascular response to exercise in COPD. Respiration Epub 2013/05/23.
   Google Scholar
• Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135(4):975–982.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530–1535.
   PubMed Web of Science ®Google Scholar